To Cite:
Khoshnood
A, Nasiri Toosi
M, Faravash
M J, Esteghamati
A, Froutan
H, et al. A Survey of Correlation Between Insulin-Like Growth Factor-I (IGF-I) Levels and Severity of Liver Cirrhosis,
Hepat Mon.
2013
; 13(2):e6181.
doi: 10.5812/hepatmon.6181.
1.
Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336(9): 633-40[DOI][PubMed]
2.
Friedrich N,
Alte D,
Volzke H,
Spilcke-Liss E,
Ludemann J,
Lerch MM,
et al.
Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res. 2008; 18(3): 228-37[DOI][PubMed]
3.
Life JS, Kipgen WW. Guidelines for the Diagnosis and Treatment of Adult Growth Hormone Deficiency 2011;
4.
Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989; 10(1): 68-91[PubMed]
6.
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16(1): 3-34[PubMed]
7.
Chen YH, Hung PF, Kao YH. IGF-I downregulates resistin gene expression and protein secretion. Am J Physiol Endocrinol Metab. 2005; 288(5)-27[DOI][PubMed]
8.
Thoren MC, Wivall-Helleryd IL, Blum WF, Hall KE. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol. 1994; 131(1): 33-40[PubMed]
9.
Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol. 1997; 27(5): 796-802[PubMed]
10.
Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest. 1991; 14(4): 317-21[PubMed]
11.
Cuneo RC,
Hickman PE,
Wallace JD,
Teh BT,
Ward G,
Veldhuis JD,
et al.
Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol (Oxf). 1995; 43(3): 265-75[PubMed]
12.
Donaghy A,
Ross R,
Wicks C,
Hughes SC,
Holly J,
Gimson A,
et al.
Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology. 1997; 113(5): 1617-22[PubMed]
13.
Scharf JG,
Schmitz F,
Frystyk J,
Skjaerbaek C,
Moesus H,
Blum WF,
et al.
Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol. 1996; 25(5): 689-99[PubMed]
14.
Shmueli E, Stewart M, Alberti KG, Record CO. Growth hormone, insulin-like growth factor-1 and insulin resistance in cirrhosis. Hepatology. 1994; 19(2): 322-8[PubMed]
15.
Chang TC, Lin JJ, Yu SC, Chang TJ. Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology. 1990; 11(1): 123-6[PubMed]
16.
Donaghy AJ, Delhanty PJ, Ho KK, Williams R, Baxter RC. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol. 2002; 36(6): 751-8[PubMed]
17.
Shen XY,
Holt RI,
Miell JP,
Justice S,
Portmann B,
Postel-Vinay MC,
et al.
Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab. 1998; 83(7): 2532-8[PubMed]
18.
Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology. 1995; 21(3): 680-8[PubMed]
19.
Petersen KF, Jacob R, West AB, Sherwin RS, Shulman GI. Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis. Am J Physiol. 1997; 273(6 Pt 1)-93[PubMed]
20.
Shmueli E, Miell JP, Stewart M, Alberti KG, Record CO. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology. 1996; 24(1): 127-33[DOI][PubMed]
21.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8): 646-9[PubMed]
22.
Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3): 797-805[DOI][PubMed]
23.
Wiesner R,
Edwards E,
Freeman R,
Harper A,
Kim R,
Kamath P,
et al.
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124(1): 91-6[DOI][PubMed]
24.
Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterol. 2003; 50(51): 814-6[PubMed]
25.
Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol. 2004; 10(18): 2740-3[PubMed]
26.
Lou M, Song N, Jin X, Luo SQ, Wang JJ. [Detection of serum free insulin-like growth factor 1 in patients with chronic viral hepatitis]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001; 15(3): 291-2[PubMed]
Readers' Comments